<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fluvoxamine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00176</strong>&#160; (APRD00425)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other <span class="caps">SSRI</span> drugs, it is most often used to treat obsessive-compulsive disorder.<br>
Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00176/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00176/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00176.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00176.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00176.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00176.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00176.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00176">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Fluvoxamina</td><td>Spanish</td><td>INN</td></tr><tr><td>Fluvoxaminum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fluvoxamine maleate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000879/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000879/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000879">DBSALT000879</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Dumirox</td><td>Abbott</td></tr><tr><td>Faverin</td><td>Abbott</td></tr><tr><td>Fevarin</td><td>Abbott</td></tr><tr><td>Floxyfral</td><td>Abbott</td></tr><tr><td>Luvox</td><td>Abbott</td></tr><tr><td>Maveral</td><td>Abbott</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antidepressive-agents-second-generation">Antidepressive Agents, Second-Generation</a></li>
<li><a href="/mesh/anti-anxiety-agents">Anti-Anxiety Agents</a></li>
<li><a href="/mesh/serotonin-uptake-inhibitors">Serotonin Uptake Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>54739-18-3</td></tr><tr><th>Weight</th><td>Average: 318.3346<br>Monoisotopic: 318.155512541</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>21</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>CJOFXWAVKWHTFT-XSFVSMFZSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Alternative parents</th><td>Oxime Ethers; Polyamines; Ethers; Monoalkylamines; Imines; Organofluorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>oxime ether; ether; polyamine; organonitrogen compound; primary amine; amine; organofluoride; organohalogen; imine; primary aliphatic amine; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzene and substituted derivatives. These are aromatic compounds containing at least one benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.</td></tr><tr><th>Pharmacodynamics</th><td>Fluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. <i>In vitro</i> studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT<sub>1A</sub>, 5HT<sub>1B</sub>, 5HT<sub>2</sub>), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Fluvoxamine does not inhibit monoamine oxidase.</td></tr><tr><th>Mechanism of action</th><td>The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for &#945;<sub>1</sub>- or &#945;<sub>2</sub>-adrenergic, &#946;-adrenergic, muscarinic, dopamine D<sub>2</sub>, histamine H<sub>1</sub>, GABA-benzodiazepine, opiate, 5-HT<sub>1</sub>, or 5-HT<sub>2</sub> receptors.</td></tr><tr><th>Absorption</th><td>Well absorbed, bioavailability of fluvoxamine maleate is 53%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>25 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>~77-80% (plasma protein)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Fluvoxamine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li></ul></td><td><a href="/metabolites/DBMET00250">fluvoxamino acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/251">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. Approximately 2% of fluvoxamine was excreted in urine unchanged. Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.</td></tr><tr><th>Half life</th><td>15.6 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Side effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9775</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5149</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6079</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7883</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5325</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8595</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6723</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8949</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7959</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8481</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.637
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6997 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8427
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7995
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Jazz pharmaceuticals</li>
<li>Actavis elizabeth llc</li>
<li>Apotex inc</li>
<li>Barr laboratories inc</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Genpharm inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Synthon pharmaceuticals ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Ani pharmaceuticals inc</li>
<li>Solvay pharmaceuticals</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Anip Acquisition Co.</li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Barr Pharmaceuticals</li>
<li>Bay Pharma Inc.</li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.elan.com">Elan Pharmaceuticals Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.excella-pharma-source.de">Excella GmbH</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.jazzpharma.com">Jazz Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.synthon.com">Synthon Pharmaceuticals Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td>100 mg </td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>25 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>50 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Fluvoxamine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Fluvoxamine may increase the effect and toxicity of aminophylline.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00182">Amphetamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Fluvoxamine may increase the anticoagulant effect of anisindione by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Fluvoxamine is a CYP1A2 inhibitor that increases exposure of asenapine by 30%. </td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion. </td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Fluvoxamine increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00395">Carisoprodol</a></td><td>Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</td></tr><tr><td><a href="/drugs/DB01166">Cilostazol</a></td><td>Fluvoxamine increases the effect of cilostazol</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>The antidepressant increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Fluvoxamine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Fluvoxamine increases the effect and toxicity of duloxetine</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Fluvoxamine may increase the therapeutic and adverse effects of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Combination associated with possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The SSRI, fluvoxamine, increases serum levels of lithium.</td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Fluvoxamine increases the effect and toxicity of methadone</td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00379">Mexiletine</a></td><td>Fluvoxamine may increase the therapeutic and adverse effects of mexiletine.</td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Fluvoxamine may increase the therapeutic and adverse effects of mirtazapine.</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Increased incidence of adverse effects with this association</td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00334">Olanzapine</a></td><td>Fluvoxamine increases the effect and toxicity of olanzapine</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Fluvoxamine may increase the therapeutic and adverse effects of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB00497">Oxycodone</a></td><td>Increased risk of serotonin syndrome</td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Fluvoxamine may increase the therapeutic effect of phenytoin.</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Fluvoxamine may increase the serum level and toxicity of ramelteon.</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Increases roflumilast levels. </td></tr><tr><td><a href="/drugs/DB00268">Ropinirole</a></td><td>Increases the effect and toxicity of ropinirole</td></tr><tr><td><a href="/drugs/DB00296">Ropivacaine</a></td><td>Increases the effect and toxicity of ropivacaine</td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort increases the effect and toxicity of the SSRI, fluvoxamine.</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of tacrine.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Fluvoxamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluvoxamine if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Fluvoxamine may increase the therapeutic and adverse effects of theophylline.</td></tr><tr><td><a href="/drugs/DB00730">Thiabendazole</a></td><td>The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>The strong CYP1A2 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Fluvoxamine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Fluvoxamine inhibits the metabolism and clearance of tizanidine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizures.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP2C19 inhibitor, fluvoxamine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Additive modulation of serotonin activity may also increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome and changes in therapeutic and adverse effects of trimipramine if fluvoxamine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Fluvoxamine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid high doses of caffeine.</li>
<li>Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>